NeuroSense Therapeutics Ltd. issued a press release on November 2, 2026, announcing an updated timeline and expanded data package for its planned New Drug Submission to Health Canada for PrimeC, its investigational ALS therapy.

Key Highlights

  • Revised filing target: The Health Canada New Drug Submission for PrimeC is now planned for March 2027, updated from the previously announced December 2026 timetable.
  • Health Canada confirmation: According to the filing, Health Canada confirmed it has no concerns with the revised timing.
  • New NfL analysis added: The expanded package will incorporate a neurofilament light chain (NfL) analysis alongside Phase 2b PARADIGM results published in JAMA Neurology and additional unpublished data from that trial.
  • NfL findings: The company disclosed that PrimeC-treated participants demonstrated a greater reduction in NfL compared to placebo, with a more pronounced effect in participants with higher baseline functionality.
  • First-ever marketing application: The planned NDS would be PrimeC's first marketing application in any jurisdiction.
  • Target population: If approved, PrimeC would address approximately 4,000 Canadians living with ALS, with approximately 1,000 new diagnoses each year, according to the filing.
  • Standard review period: Health Canada's standard review target for an NDS is approximately 300 calendar days following acceptance.

NeuroSense Expands PrimeC Submission Package Ahead of March 2027 Health Canada Filing

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) disclosed on November 2, 2026, that it is incorporating newly generated data into its planned New Drug Submission (NDS) to Health Canada for PrimeC, its lead investigational therapy for amyotrophic lateral sclerosis (ALS). The company reported that the decision to expand the package prompted a shift in the filing target from December 2026 to March 2027, and that Health Canada confirmed no concerns with the revised schedule.

According to the filing, the expanded submission will combine the Phase 2b PARADIGM trial results, previously published in JAMA Neurology, with a new neurofilament light chain (NfL) analysis and additional unpublished data from that trial. The company stated that PrimeC-treated participants demonstrated a greater reduction in NfL levels compared to placebo, with a more pronounced effect observed in participants with higher baseline functionality. The filing noted that additional statistical analyses are underway to further characterize these findings before they are incorporated into the submission.

The company also disclosed that it has completed the pre-submission process and reached alignment with Health Canada on the proposed submission content and structure. In parallel, NeuroSense reported it is advancing discussions with potential commercialization partners in Canada. The filing noted that the company is also preparing for its FDA-cleared U.S. Phase 3 PARAGON trial in ALS. All statements regarding anticipated timelines, regulatory outcomes, and partnership discussions are characterized in the filing as forward-looking statements subject to risks and uncertainties, including delays in completing analyses, the possibility that Health Canada may request additional information, and uncertainty in estimates of the ALS patient population in Canada.

What Was Disclosed

NeuroSense announced on November 2, 2026, that it is expanding the data package for its planned Health Canada NDS for PrimeC and updating the filing target to March 2027, with Health Canada confirming no concerns about the revised timing.